Medlab Clinical (ASX:MDC) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MDC Stock Overview

Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia.

About the company

MDC fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Revenue is forecast to grow 41.74% per year

Trading at good value compared to peers and industry

Risk Analysis

Shares are highly illiquid

Earnings are forecast to decline by an average of 44.7% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap (A$15M)

+ 1 more risk

Medlab Clinical Limited Competitors

Immuron

ASX:IMC

AU$23.9m

Cynata Therapeutics

ASX:CYP

AU$37.7m

Noxopharm

ASX:NOX

AU$17.8m

AdAlta

ASX:1AD

AU$15.2m

Price History & Performance

Summary of all time highs, changes and price drops for Medlab Clinical
Historical stock prices
Current Share Price	AU$6.60
52 Week High	AU$14.94
52 Week Low	AU$6.45
Beta	1.1
1 Month Change	0%
3 Month Change	-4.21%
1 Year Change	-43.59%
3 Year Change	-79.05%
5 Year Change	-91.85%
Change since IPO	-78.00%

Recent updates

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Oct 06

Shareholder Returns

	MDC	AU Biotechs	AU Market
7D	0%	2.9%	0.4%
1Y	-43.6%	-7.5%	6.0%

Return vs Industry: MDC underperformed the Australian Biotechs industry which returned 11.4% over the past year.

Return vs Market: MDC underperformed the Australian Market which returned -1.5% over the past year.

Price Volatility

Is MDC's price volatile compared to industry and market?
MDC volatility
MDC Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.3%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.6%
10% least volatile stocks in AU Market	3.5%

Stable Share Price: MDC has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine MDC's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2012	n/a	Sean Hall	www.medlab.co

Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. Its drug candidate includes NanaBis, a buccal spray from cannabis oil extract for oncology and pain management; and NanoCBD, a buccal spray from hemp oil extract for mental health. The company also develops NanoCelle, a patented sub-micron drug delivery platform that allows passive diffusion of active pharmaceutical ingredients directly into the bloodstream through oral-buccal, sublingual, intranasal, and transdermal or topical delivery.

Medlab Clinical Limited Fundamentals Summary

How do Medlab Clinical's earnings and revenue compare to its market cap?
MDC fundamental statistics
Market cap	AU$15.07m
Earnings (TTM)	-AU$8.32m
Revenue (TTM)	AU$1.54m

9.8x

P/S Ratio

-1.8x

P/E Ratio

Is MDC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MDC income statement (TTM)
Revenue	AU$1.54m
Cost of Revenue	AU$336.29k
Gross Profit	AU$1.20m
Other Expenses	AU$9.52m
Earnings	-AU$8.32m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-3.64
Gross Margin	78.11%
Net Profit Margin	-541.67%
Debt/Equity Ratio	0%

How did MDC perform over the long term?

See historical performance and comparison

This company listing is no longer active

MDC Stock Overview

Rewards

Risk Analysis

Medlab Clinical Limited Competitors

ASX:IMC

AU$23.9m

ASX:CYP

AU$37.7m

ASX:NOX

AU$17.8m

ASX:1AD

AU$15.2m

Price History & Performance

Recent News & Updates

Consensus EPS estimates upgraded to AU$2.29 loss, revenue downgraded

Consensus forecasts updated

Price target decreased to AU$18.84

Medlab Announces Interim Readout of Rwe Medcare Study

Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Recent updates

Consensus EPS estimates upgraded to AU$2.29 loss, revenue downgraded

Consensus forecasts updated

Price target decreased to AU$18.84

Medlab Announces Interim Readout of Rwe Medcare Study

Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Medlab Clinical Limited Provides NanoCelle Nasal RNA (Nucleid Acid) Program Update

Medlab Clinical Limited Provides NanaBis and NanoCBD Clinical Development Update

Less than half of directors are independent

Medlab Clinical Limited Announces the Resignation of Laurence McAllister as Non-Executive Director

Full year 2022 earnings: Revenues exceed analyst expectations

Medlab Clinical Limited, Annual General Meeting, Sep 30, 2022

Medlab Clinical Ltd Announces the European Patent Office Has Formalised ACCEPTANCE of the Depression Patent, and Within the Next 2-3 Months Will Be Granted

Medlab Clinical Limited Appoints Mohit Gupta as an Independent Non-Executive Director, Effective August 8, 2022

Medlab Clinical Ltd Updates Shareholders on the Progress of Our NanoCelle NanaBis Program

Medlab Clinical Ltd Announces Update on Progression of NanoCelle NASAL COVID-19 Vaccine Program

Less than half of directors are independent

Medlab Clinical Ltd Announces Update on NanoCBDTM

Medlab Clinical Ltd Announces the Receipt of "Favorable Opinion" Status from the UK Research Ethics Committee for the Forthcoming Nanabistm Phase 3 Trial, with No Additional Conditions or Submission Required

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?

Full year 2021 earnings released: AU$0.042 loss per share (vs AU$0.059 loss in FY 2020)

Medlab Receives Phase 3 NanaBi Trials Approval from the Australian Government, with Clinical Trials Number for Cancer Bone Pain

Australian Ethics Grants Approval for Medlab's NanaBisTM PIII Australian Sites

CFO, Company Secretary & COO has left the company

Medlab Clinical Limited announced that it expects to receive AUD 15 million in funding

Medlab Clinical Limited Appoints Cheryl Maley as an Independent Non-Executive Director

First half 2021 earnings released: AU$0.019 loss per share (vs AU$0.033 loss in 1H 2020)

What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay

Medlab Executes Australian Exclusive Non-Binding Heads of Agreement with Arrotex Australia Group Australia Pty Ltd

Medlab Clinical Limited Receives Positive Depression Trial Prelim Results

New 90-day high: AU$0.36

Medlab Clinical Announces US FDA Grants Investigational New Drug (IND) Status for Nanabistm

Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years

Medlab Clinical Provides an Update on Clinical and Pre-Clinical Programs Currently Underway

Medlab Clinical Limited Announces NanaBis Observational Study Progression Report

New 90-day high: AU$0.26

Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future

Medlab Clinical Limited Announces NanaBisTM PIII Trial Launching in the Uk with Support from the National Institute for Health Research

New 90-day high: AU$0.21

Full year earnings released - AU$0.059 loss per share

Medlab Clinical Limited has completed a Follow-on Equity Offering in the amount of AUD 1.570476 million.

Medlab Clinical Limited announced that it has received AUD 5.397603 million in funding